



## Theracryf plc

("Theracryf", the "Company" or the "Group")

### Issue of Equity and Total Voting Rights

Alderley Park, UK - 14 Nov 2024: Theracryf plc (AIM: TCF) the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company has issued 2,275,527 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") in lieu of professional fees.

Application will be made for 2,275,527 Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 20 November 2024 and the Ordinary Shares will, on issue, rank pari passu in all respects with the Company's existing Ordinary Shares.

On Admission, the Company will have a total of 429,622,422 Ordinary Shares in issue. No Ordinary Shares are held in treasury. The figure of 429,622,422 may be used by the Company's shareholders as the denominator in the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure, Guidance and Transparency Rules.

-Ends-

#### Enquiries

**Theracryf plc**  
Dr Huw Jones, CEO  
Toni Hänninen, CFO  
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090  
[enquiries@theracryf.com](mailto:enquiries@theracryf.com)

**Cavendish Capital Markets (NOMAD and Broker)**  
Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)  
Nigel Birks / Harriet Ward (ECM)

+44 20 7220 0500

**Vigo Consulting**  
Rozi Morris

+44 207 7390 0230  
[theracryf@vigoconsulting.com](mailto:theracryf@vigoconsulting.com)

#### About Theracryf

Theracryf is a clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma\*, neurodevelopmental disorders, addiction, anxiety and narcolepsy\* [\*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation, including Stalicia SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

Theracryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF.

For further information, please visit: [www.theracryf.com](http://www.theracryf.com)

END

IOEQKQBBPBDBDD